Video

Conclusions on Treating Carcinoid Crisis Without Perioperative Octreotide for Patients With Neuroendocrine Tumors

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, provides conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.

During the interview, Pommier provided conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Related Videos
Hands holding a crochet heart | Image Credit: © StockerThings - stock.adobe.com
Wooden blocks spelling HDL, LDL | Image Credit: © surasak - stock.adobe.com
Anticoagulant attacking blood clot | Image Credit: © BURIN93 - stock.adobe.com
Depiction of man aging | Image Credit: © Top AI images - stock.adobe.com
Map with pins | Image Credit: © Tryfonov - stock.adobe.com
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Image Credit: © abricotine - stock.adobe.com
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.